Highest-materiality recent filing
Crescent Biopharma shareholders re-elect directors, ratify auditor, approve say-on-pay
Jonathan Violin, Ph.D. elected Class II director with 2,890,000 votes (all from preferred shares).
Crescent Biopharma Q1 net loss $23.3M; cash $189.2M funds ops into 2028
Net loss $23.3M ($0.70/sh) vs $15.1M ($19.63/sh) in Q1 2025; revenue $1.0M from Kelun-Biotech license.
Crescent Biopharma reports FY2025 net loss $153.9M, revenue $10.8M; cash $213.2M
Net loss of $92.4M ($4.01 per share) for Q4 2025 vs. $15.2M in prior year; FY net loss $153.9M.
Crescent Biopharma partners with Kelun-Biotech on CR-001/SKB105, raises $185M
Licenses CR-001 to Kelun-Biotech for Greater China; receives $20M upfront and up to $30M milestones.
Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track
Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.
Crescent Biopharma Q2 net loss $21.8M; merger & $200M financing closed
Net loss $21.8M ($4.93/share) for Q2 2025; R&D $12.1M, G&A $8.9M.
Crescent Biopharma completes reverse merger with GlycoMimetics; post-merger shares trade under CBIO
Former GlycoMimetics securityholders own ~2.7% of combined company; Crescent holders own ~97.3% on fully diluted basis.
Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split
Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.
GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE
GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.
GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share
Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.
GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart
Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.
GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities
Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.
CEO and CFO to depart GlycoMimetics by March 31; will consult through merger close
CEO Harout Semerjian and CFO Brian Hahn notified board of intent to resign by March 31, 2025.
GlycoMimetics files updated investor presentation for Crescent Biopharma merger
Investor presentation for proposed merger with Crescent Biopharma updated as of January 2025.
GlycoMimetics gets Nasdaq extension to June 16, 2025; stock transferred to Capital Market
Received 180-day extension until June 16, 2025 to meet $1.00 minimum bid price for continued listing.
GlycoMimetics and Crescent update merger investor presentation; no new deal terms disclosed
GlycoMimetics furnished updated investor presentation (Exhibit 99.1) for proposed merger with Crescent Biopharma.
GlycoMimetics merges with Crescent in reverse acquisition; uproleselan trial fails
Crescent stockholders will own ~86.21% of combined company; GlycoMimetics stockholders ~13.79%.
GlycoMimetics cuts 80% workforce, begins strategic review after FDA setback for uproleselan
FDA feedback requires an additional clinical trial for uproleselan in R/R AML; regulatory path uncertain.
GlycoMimetics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on June 21, 2024 for bid price below $1.00 for 30 consecutive business days.
GlycoMimetics grants performance-based stock options to NEOs vesting on FDA approval of uproleselan
CEO Harout Semerjian granted 521,250 shares; CFO Brian Hahn and CMO Edwin Rock each granted 187,500 shares.
Phase 3 missed primary endpoint: mOS 13.0 vs 12.3 months (HR 0.89; 95% CI 0.69-1.15), not statistically significant.
Phase 3 study (388 patients) of uproleselan + chemo did not achieve statistically significant improvement in overall survival vs chemo alone.
Stockholders voted to increase authorized common stock from 100M to 150M shares (49.3M for, 1.0M against).
GlycoMimetics reports Q4/FY2023 cash $41.8M; Phase 3 uproleselan topline in Q2 2024
Cash and equivalents $41.8M at Dec 31, 2023, down from $47.9M at Dec 31, 2022.
GlycoMimetics files 8-K with corporate presentation; no material updates disclosed
Filing includes a slide presentation for anticipated investor meetings, March 2024.
GlycoMimetics signs commercial manufacturing deal with Thermo Fisher's Patheon for uproleselan
Agreement covers commercial supply of injectable uproleselan if FDA approves the drug.
GlycoMimetics Q3 cash $49.4M; uproleselan Phase 3 topline by Q2 2024; NDA filing by end 2024
Cash and cash equivalents $49.4M as of Sep 30, 2023; no revenue reported (pre-revenue biotech).
GlycoMimetics Q2 cash $58M; uproleselan Phase 3 topline by Q2 2024; GMI-1687 Phase 1a in Q3
Cash $58.0M at June 30, 2023, up from $47.9M at Dec 31, 2022; R&D spend $4.1M, down 49% YoY.
GlycoMimetics stockholders elect all director nominees, ratify auditor, approve say-on-pay
Three director nominees elected: Andrews (36.2M for, 0.5M withheld), Goldberg (32.6M/4.0M), Pearson (36.3M/0.4M); 14.2M broker non-votes.
GlycoMimetics Q1 cash $65M; uproleselan Phase 3 trial on track for H1 2024 survival trigger
Cash and equivalents $65.0M as of March 31, 2023, up from $47.9M at Dec 31, 2022; raised $28.7M via ATM.
GlycoMimetics amends lease: reduces footprint by ~12,000 sq ft, extends remaining to Jan 2025
Lease for ~42,000 sq ft in Rockville, MD amended; ~12,000 sq ft terminates Oct 31, 2023; remaining ~30,000 sq ft extended to Jan 31, 2025.
GlycoMimetics reports $47.9M cash; Phase 3 uproleselan trial continues to final events in H1 2024
Cash and equivalents $47.9M at Dec 31, 2022; raised $28.7M net from ATM in Q1 2023.
GlycoMimetics discloses $2M deposit at Silicon Valley Bank; says amount immaterial
Company holds approximately $2M in cash deposits at Silicon Valley Bank.
Filing includes a slide presentation dated March 2, 2023, for anticipated investor meetings.
GlycoMimetics CSO John Magnani to depart March 31; consulting through June 2024
Dr. John Magnani, SVP Research and CSO, employment ends March 31, 2023.
GlycoMimetics reports Q3 2022 financials; FDA clears interim analysis for uproleselan Phase 3
Cash $51.6M as of Sep 30, 2022 vs $90.3M at Dec 31, 2021; cash runway extended to end of 2023.
GlycoMimetics files 8-K with slide presentation for investor meetings; content not disclosed
Slide presentation furnished as Exhibit 99.1 for investor meetings on October 4, 2022.
GlycoMimetics Q2 cash $60.2M; FDA clears GMI-1687 IND; uproleselan Phase 3 data expected mid-2023
Cash and cash equivalents $60.2M as of June 30, 2022, down from $90.3M at Dec 31, 2021.
GlycoMimetics receives Nasdaq minimum bid price deficiency notice
Bid price below $1.00 for 30 consecutive business days; 180-day cure period until Nov 28, 2022.
GlycoMimetics stockholders approve 2.6M share increase to equity incentive plan
Stockholders approved amendment to 2013 Equity Incentive Plan, increasing share reserve by 2,619,622 shares.
GlycoMimetics Q1 cash $76.5M; Phase 3 uproleselan OS events trigger now mid-2023; workforce cut 20%
Cash and cash equivalents $76.5M at March 31, 2022, down from $90.3M at Dec 31, 2021.
GlycoMimetics reports cash $90.3M; Phase 3 uproleselan data still after 2022
Cash and equivalents $90.3M at Dec 31, 2021 vs $137.0M at Dec 31, 2020; revenue fell to $1.2M from $10.2M.
GlycoMimetics awards retention bonuses to CFO, CBO, CSO; induces plan shares to 3M
CFO Brian Hahn and CBO Armand Girard eligible for retention bonus up to 60% of base salary; CSO John Magnani up to 20%.
GlycoMimetics Q3 cash $101.9M; uproleselan Phase 3 enrollment nearing completion
Cash and cash equivalents $101.9M at Sept 30, 2021, down from $137.0M at Dec 31, 2020.
GlycoMimetics names Harout Semerjian CEO to succeed retiring Rachel King; Q2 cash $118.9M
CEO Rachel King retires effective Aug 6, 2021; remains on board and as consultant. Harout Semerjian appointed CEO effective Aug 6.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
Mr. Brian Hahn, the Company’s Chief Financial Officer, notified the Company’s board of directors of his intent to cease his respective employment with the Company no later than March 31, 2025.
the employment of Dr. Edwin Rock, the Company’s Chief Medical Officer, will end on July 31, 2024
On February 21, 2023, GlycoMimetics, Inc. (the “ Company ”) and Dr. John Magnani, the Company’s Senior Vice President of Research and Chief Scientific Officer, entered into an agreement (the “ Transition Agreement ”) pursuant to which the Company and Dr. Magnani have agreed that his employment with the Company will end on March 31, 2023
On August 2, 2021, the Board appointed Harout Semerjian as the Company’s President and Chief Executive Officer, effective as of August 6, 2021.
On July 30, 2021, Rachel K. King, President and Chief Executive Officer of the Company, notified the Board of Directors of the Company (the “ Board ”) of her decision to retire from those positions, effective as of August 6, 2021.
Max materiality 1.00 · Median 0.65 · Most common event other_material